ClinicalTrials.gg
CompletedNCT04449861Updated Nov 27, 2024Results posted

Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)

A Phase 3 interventional study of Durvalumab plus chemotherapy in Small Cell Lung Carcinoma Extensive Disease, sponsored by AstraZeneca. Completed at 30 sites in China. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
166
Allocation
Not applicable
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing durvalumab in Small Cell Lung Carcinoma — 10 open to participants now, 19 under way, 3 of them phase 3. durvalumab · Small Cell Lung Carcinoma.

Enrollment
4th of 36
166 · median 50
Started
2020
with 3 others
Phase 3
6 of 36
none open now
Registered
11th of 36
by date
Lead sponsor
12 of 36
AstraZeneca

Among the 36 studies testing durvalumab in Small Cell Lung Carcinoma, this one is the 4th largest by enrollment, is one of 4 that started in 2020, is one of 6 in phase 3, and was the 11th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

10 of the 36 studies testing durvalumab in Small Cell Lung Carcinoma are open now, in 8 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing durvalumab in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This will be an open-label, single-arm, multicenter, Phase IIIb study to determine the safety of durvalumab + etoposide and cisplatin or carboplatin as first-line treatment in patients with extensive stage small-cell lung cancer.

03

Conditions studied

  • Small Cell Lung Carcinoma Extensive Disease
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

For inclusion in the study, patients should fulfill the following criteria:

  1. Male or female ≥18 years at the time of Screening.
  2. Written obtained from the patient/legal representative prior to performing any protocol-related procedures, including screening evaluations.
  3. or cytologically documented extensive stage SCLC (stage IV [T any, N any, M1 a/b], or with T3-4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan, according to American Joint Committee on Cancer Stage 8th edition).

    • ; must be asymptomatic or treated and stable off and anti-convulsants for at least 1 month prior to study treatment. Patients with suspected brain metastases at screening should have a CT/MRI of the brain prior to study entry.
  4. Patients must be considered suitable to receive a platinum-based chemotherapy regimen as treatment for the ES-SCLC. Chemotherapy must contain either cisplatin or carboplatin in combination with etoposide.
  5. ≥12 weeks at Day 1.
  6. World Health Organization (WHO)/ (ECOG) Performance Status of 0 to 2 at enrollment.

    • Note: Patients with PS2 will be limited to a maximum of 20% of the total study population; once this limit is met, additional enrolled patients must have PS 0-1.
  7. Body weight >30 kg.
  8. At least 1 lesion, not previously irradiated, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have a short axis ≥15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI) and that is suitable for accurate repeated measurements as per 1.1 guidelines.
  9. Baseline CT/MRI results of the chest and abdomen (including liver and adrenal glands) within 28 days prior to the treatment initiation.
  10. No prior exposure to immune-mediated therapy including, but not limited to, other , anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
  11. Adequate organ and marrow function as defined below (test can be repeated once if necessary):

    • ≥9.0 g/dL.
    • ≥1.5 × 10\^9/L (use of granulocyte colony-stimulating factor is not permitted at within 7 days before testingscreening).
    • count ≥100 × 10\^9/L.
    • Serum ≤1.5 × the (ULN).
    • In patients without hepatic : and AST ≤2.5 × ULN.
    • In patients with hepatic metastases, ALT and AST ≤5 × ULN.
    • Measured or calculated : >60mL/min for patients planned to be treated with cisplatin and >40mL/min for patients planned to be treated with carboplatin
  12. Evidence of status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.

The following age-specific requirements apply:

  • Women \<50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).
  • Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

  1. Previous IP assignment in the present study.
  2. Medical to etoposide-platinum (carboplatin or cisplatin)-based chemotherapy.
  3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
  4. Received prior systemic therapy for ES-SCLC. Patients who have received prior chemoradiotherapy for limited-stage SCLC must have been treated with curative intent and experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle from diagnosis of ES-SCLC
  5. Any condition that, in the opinion of the treating physician, would interfere with evaluation of the study drug or interpretation of patient safety.
  6. Planned consolidation chest radiation therapy. Radiation therapy outside of the chest for palliative care (ie, bone metastasis) is allowed but must be completed before first dose of the study medication.
  7. Major surgical procedure (as defined by the investigator) within 28 days prior to the first dose of IP. Note: Local surgery of isolated lesions for palliative intent is acceptable.
  8. History of allogeneic organ transplantation.
  9. Has a paraneoplastic syndrome (PNS) of nature, requiring systemic treatment (systemic steroids or agents) or has a clinical symptomatology suggesting worsening of PNS.
  10. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis with the exception of diverticulosis, systemic lupus erythematosus, sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, and uveitis, etc]). The following are exceptions to this criterion:

    • Patients with vitiligo or alopecia
    • Patients with hypothyroidism (eg, following Hashimoto syndrome) and stable on hormone replacement
    • Any chronic skin condition that does not require systemic therapy
    • Patients without active disease in the last 5 years may be included but only after consultation with the Study Physician
    • Patients with celiac disease controlled by diet alone
  11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
  12. History of active primary immunodeficiency.
  13. Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), (known positive HBV surface antigen [HbsAg] result), , or (positive HIV 1/2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  14. Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:

    • Intranasal, inhaled, topical steroids or local steroid injections (eg, intra articular
    • injection).
    • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
    • Steroids as premedication for reactions (eg, CT scan premedication). Premedication with steroids for chemotherapy is acceptable.
  15. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive whilst receiving IP and up to 30 days after the last dose of IP.
  16. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective from Screening to 90 days after the last dose of durvalumab.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
166 participants (actual)

Study arms

  • Experimental
    Durvalumab plus 4-6 cycles chemotherapy

    Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.

    Drug: Durvalumab plus chemotherapy

Interventions

  • DrugDurvalumab plus chemotherapy

    Drug page: Durvalumab

    Drug: Durvalumab IV infusions every 3 weeks for 4-6 cycles and every 4 weeks thereafter until PD or other discontinuation criteria. Drug: Carboplatin 4-6 cycles every 3 weeks Drug: Cisplatin 4-6 cycles every 3 weeks Drug: Etoposide 4-6 cycles every 3 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade ≥3 AEs

    Time frame: 19 months

  2. Percentage of Participants With Immune-mediated Adverse Events (imAEs)

    An immune-mediated adverse event (imAE) is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate aetiology.

    Time frame: 19 months

Secondary outcomes

  1. Median Progression Free Survival (PFS)

    PFS by investigator assessment according to RECIST v1.1 criteria Progression-free survival is defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from study therapy or receives another anti-cancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment of investigator. However, if the patient progresses or dies after 2 or more missed visits, the patient will be censored at the time of the latest assessment. If the patient has no evaluable visits or does not have baseline data, they will be censored at the day of first dose unless they die within 2 visits of baseline.

    Time frame: 19 months

  2. Proportion of Patients Alive and Progression Free at 12 Months (APF12)

    The APF12 is defined as the Kaplan-Meier estimate of PFS (per investigator assessment according to RECIST v1.1 criteria) at 12 months.

    Time frame: 12 months

  3. Objective Response Rate (ORR)

    Objective Response Rate is defined as the number (%) of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained up until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR. Any CR or PR which occurred after a further anti-cancer therapy was received will not be included in the numerator for the ORR calculation.

    Time frame: 19 months

  4. Median Overall Survival (OS)

    Overall survival is defined as the time from the date of first dose of study treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

    Time frame: 19 months

  5. Proportion of Patients Alive at 12 Months (OS12)

    The OS12 is defined as the Kaplan-Meier estimate of OS at 12 months

    Time frame: 12 months

  6. Duration of Response (DOR)

    Duration of response is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR.

    Time frame: 19 months

  7. Percentage of Participants With AEs

    Time frame: 19 months

  8. Percentage of Participants With SAEs

    Time frame: 19 months

  9. Percentage of Participants With Adverse Events of Special Interest (AESI)

    Time frame: 19 months

  10. Percentage of Participants With AEs Resulting in Treatment Discontinuation

    Time frame: 19 months

07

Results

Posted Nov 27, 2024

Participant flow

The study recruited the first participant on 07 December 2020 and the last participant's last visit was completed on 30 March 2023. A total of 193 participants were screened, among which, 166 participants (86.0%) were successfully enrolled into the study from 32 study sites in China

Participant flow — Overall Study
MilestoneDurvalumab With EP
Started166
Completed45
Not completed121
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up5
Withdrew: Death112

Outcome measures

PrimaryPercentage of Participants With Grade ≥3 AEs
Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With Grade ≥3 AEs
percentage of participantsDurvalumab With EP
Percentage of Participants With Grade ≥3 AEs49.7
PrimaryPercentage of Participants With Immune-mediated Adverse Events (imAEs)

An immune-mediated adverse event (imAE) is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate aetiology.

Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With Immune-mediated Adverse Events (imAEs)
percentage of participantsDurvalumab With EP
Percentage of Participants With Immune-mediated Adverse Events (imAEs)24.2
SecondaryMedian Progression Free Survival (PFS)

PFS by investigator assessment according to RECIST v1.1 criteria Progression-free survival is defined as the time from first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from study therapy or receives another anti-cancer therapy prior to progression. Patients who have not progressed or died at the time of analysis will be censored at the time of the latest date of assessment of investigator. However, if the patient progresses or dies after 2 or more missed visits, the patient will be censored at the time of the latest assessment. If the patient has no evaluable visits or does not have baseline data, they will be censored at the day of first dose unless they die within 2 visits of baseline.

Time frame:
19 months
Reported as:
Median · months
Median Progression Free Survival (PFS)
monthsDurvalumab With EP
Median Progression Free Survival (PFS)6.3 (5.6 to 6.5)
SecondaryProportion of Patients Alive and Progression Free at 12 Months (APF12)

The APF12 is defined as the Kaplan-Meier estimate of PFS (per investigator assessment according to RECIST v1.1 criteria) at 12 months.

Time frame:
12 months
Reported as:
Number · percentage of participants
Proportion of Patients Alive and Progression Free at 12 Months (APF12)
percentage of participantsDurvalumab With EP
Proportion of Patients Alive and Progression Free at 12 Months (APF12)17.6 (12.0 to 24.1)
SecondaryObjective Response Rate (ORR)

Objective Response Rate is defined as the number (%) of patients with measurable disease with at least 1 visit response of CR or PR. Data obtained up until progression or last evaluable assessment in the absence of progression will be included in the assessment of ORR. Any CR or PR which occurred after a further anti-cancer therapy was received will not be included in the numerator for the ORR calculation.

Time frame:
19 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsDurvalumab With EP
Objective Response Rate (ORR)76.4 (69.1 to 82.6)
SecondaryMedian Overall Survival (OS)

Overall survival is defined as the time from the date of first dose of study treatment until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.

Time frame:
19 months
Reported as:
Median · months
Median Overall Survival (OS)
monthsDurvalumab With EP
Median Overall Survival (OS)14.8 (13.2 to 16.0)
SecondaryProportion of Patients Alive at 12 Months (OS12)

The OS12 is defined as the Kaplan-Meier estimate of OS at 12 months

Time frame:
12 months
Reported as:
Number · percentage of participants
Proportion of Patients Alive at 12 Months (OS12)
percentage of participantsDurvalumab With EP
Proportion of Patients Alive at 12 Months (OS12)60.8 (52.8 to 67.9)
SecondaryDuration of Response (DOR)

Duration of response is defined as the time from the date of first documented response until the date of documented progression or death in the absence of disease progression. The end of response should coincide with the date of progression or death from any cause used for the PFS endpoint. The time of the initial response will be defined as the latest of the dates contributing towards the first visit response of PR or CR.

Time frame:
19 months
Reported as:
Median · months
Duration of Response (DOR)
monthsDurvalumab With EP (CR+PR)
Duration of Response (DOR)5.1 (4.7 to 5.7)
SecondaryPercentage of Participants With AEs
Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With AEs
percentage of participantsDurvalumab With EP
Percentage of Participants With AEs97.6
SecondaryPercentage of Participants With SAEs
Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With SAEs
percentage of participantsDurvalumab With EP
Percentage of Participants With SAEs42.4
SecondaryPercentage of Participants With Adverse Events of Special Interest (AESI)
Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events of Special Interest (AESI)
percentage of participantsDurvalumab With EP
Percentage of Participants With Adverse Events of Special Interest (AESI)40.0
SecondaryPercentage of Participants With AEs Resulting in Treatment Discontinuation
Time frame:
19 months
Reported as:
Number · percentage of participants
Percentage of Participants With AEs Resulting in Treatment Discontinuation
percentage of participantsDurvalumab With EP
Percentage of Participants With AEs Resulting in Treatment Discontinuation12.1

Adverse events

Collected over 19 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab With EP112/165 (67.9%)70/165 (42.4%)161/165 (97.6%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventDurvalumab With EP
AnaemiaBlood and lymphatic system disorders15/165
Platelet count decreasedInvestigations14/165
MyelosuppressionBlood and lymphatic system disorders8/165
PneumoniaInfections and infestations7/165
Neutrophil count decreasedInvestigations6/165
White blood cell count decreasedInvestigations6/165
Immune-mediated lung diseaseRespiratory, thoracic and mediastinal disorders3/165
DeathGeneral disorders3/165
Urinary tract infectionInfections and infestations2/165
Cerebral infarctionNervous system disorders2/165
Most frequent other events
Most frequent other events
EventDurvalumab With EP
anaemiaBlood and lymphatic system disorders125/165
nauseaGastrointestinal disorders45/165
vomitingGastrointestinal disorders36/165
alopeciaSkin and subcutaneous tissue disorders36/165
constipationGastrointestinal disorders35/165
decreased appetiteMetabolism and nutrition disorders34/165

Baseline characteristics

165 participants who received at least 1 dose of study treatment were included in baseline analysis population

Age, Continuous
Age, Continuous(years)Durvalumab With EP
Age (years)63.70 ± 7.699
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab With EP
Sex — Female25
Sex — Male140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Durvalumab With EP
Hispanic or Latino0
Not Hispanic or Latino165
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Durvalumab With EP
American Indian or Alaska Native0
Asian165
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

30 sites
  • Research Site
    Baoding, 071000, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Dalian, 116001, China
  • Research Site
    Dongyang, 322100, China
  • Research Site
    Guangdong, 510120, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510280, China
  • Research Site
    Haerbin, 150081, China
  • Research Site
    Hangzhou, 310016, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Hefei, 230000, China
  • Research Site
    Huai'an, 223000, China
  • Research Site
    Jiangyin, 214400, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Jinhua, 321099, China
  • Research Site
    Nanchang, 330000, China
  • Research Site
    Nanjing, 210032, China
  • Research Site
    Ningbo, 315000, China
  • Research Site
    Qingdao, 266100, China
  • Research Site
    Shanghai, 200025, China
  • Research Site
    Shanghai, 200040, China
  • Research Site
    ShenZhen, 518020, China
  • Research Site
    Taizhou, 318000, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Whenzhou, 325000, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuxi, 214023, China
  • Research Site
    Yangzhou, 225012, China
  • Research Site
    Zhengzhou, 450000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Mar 2023, 27 months.

Results were first posted in Nov 2024, 1 year 7 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 27 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2020
First posted
Jun 29, 2020
StartActual
Dec 7, 2020
Primary completionActual
Mar 30, 2023
CompletionActual
Mar 30, 2023
Results first posted
Nov 27, 2024
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04449861
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 29, 2020
Start date
Dec 7, 2020
Primary completion
Mar 30, 2023
Completion
Mar 30, 2023
Results posted
Nov 27, 2024
Last update
Nov 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion